Avanir Reports Strong Revenue but Misses on Earnings

Avanir Pharmaceuticals (NASDAQ: AVNR  ) reported its fiscal second-quarter results after the market closed on Wednesday. Here are the key points that investors need to know.

Results
The company reported a net loss for the quarter of $16.5 million, or $0.12 per share. That loss reflects improvement over the net loss of $17.0 million, or $0.13 per share, for the same period in fiscal 2012. However, the net loss failed to meet analyst expectations. The average analysts' estimate called for a loss of $0.09 per share.

Avanir's revenue for the fiscal second quarter totaled $17.4 million, a 74% year-over-year increase. The revenue result met analyst expectations.

Most of the company's revenue stemmed from Nuedexta. The drug used to treat pseudobulbar affect garnered gross revenue of $20.8 million and net revenue of $16.5 million during the quarter. Avanir also received nearly $900,000 in royalties for cold sore medicine Abreva from GlaxoSmithKline (NYSE: GSK  ) .

While revenue growth was strong, the company's expenses derailed any hopes of meeting bottom-line expectations. Avanir reported total operating expenses, excluding cost of sales and share-based compensation, of $30.1 million. This figure was much higher than the $25.3 million in expenses incurred in the same quarter last year, reflecting sizable increases in research and development, selling and marketing, and general and administrative costs.

Avanir reported cash, cash equivalents, and restricted investments of $70.2 million as of the end of March. Of that total, $67.9 million came from cash and cash equivalents.

Looking ahead
The company received welcome news a couple of weeks ago from Europe. The Committee for Medicinal Products for Human Use, or CHMP, announced a positive recommendation for Nuedexta. This bodes well for ultimate approval for the drug in Europe.

Avanir also claims a couple of drugs in its pipeline with potential. AVP-923 is under evaluation in several mid-stage trials for the treatment of levodopa-induced dyskinesia in Parkinson's disease, central neuropathic pain in multiple sclerosis, and agitation in Alzheimer's disease. The company also announced positive results earlier this year from a study of experimental drug AVP-786 that shows possibility for it to treat similar indications.

Abreva loses patent protection in the U.S. in April. This likely means less royalty payments from Glaxo in the not-so-distant future. However, those royalties aren't very large, so this won't be a significant negative for Avanir.

My view is that Nuedexta sales will continue to experience strong growth in the U.S. and get a nice bump if European approval is granted, which I expect will be the case. Avanir does need to get its expenses under control somewhat to please analysts. The latest quarterly results could drive shares down with the earnings miss. However, for investors willing to take on some risk, Avanir offers good upside potential.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2420086, ~/Articles/ArticleHandler.aspx, 4/21/2014 11:11:08 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement